GLPwatch
Papers (12034)
Page 110 of 201, ranked by citation count.
- Tirzepatide-Related Acute Liver Injury.
- Self-Assembly of Exendin-4-Derived Dual Peptide Agonists is Mediated by Acylation and Correlated to the Length of Conjugated Fatty Acyl Chains.
- Exendin-4 Reversed the PC12 Cell Damage Induced by circRNA CDR1as/miR-671/GSK3β Signaling Pathway.
- Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
- Impact of liraglutide on microcirculation in experimental diabetic cardiomyopathy.
- Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.
- Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience.
- Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management.
- Improving Adherence to Weight-Loss Medication (Liraglutide 3.0 mg) Using Mobile Phone Text Messaging and Healthcare Professional Support.
- CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
- Tirzepatide: a new low for bodyweight and blood glucose.
- A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate model.
- Combination therapy in recent-onset type 1 diabetes.
- The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes.
- Olfactory dysfunction in type II diabetes: Therapeutic options and lessons learned from other etiologies - A scoping review.
- Effect of liraglutide on cardiometabolic profile and on bioelectrical impedance analysis in patients with obesity and metabolic syndrome.
- Semaglutide for weight loss.
- The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes.
- Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
- Alzheimer’s disease: the new promise.
- Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.
- The new dual gastric inhibitory peptide/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?
- Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs.
- Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies Treatment.
- Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats.
- Pharmacological treatment of non-responders following bariatric surgery.
- Tirzepatide for Weight Loss: Can Medical Therapy "Outweigh" Bariatric Surgery?
- A Research Update on Exendin-4 as a Novel Molecule Against Parkinson's Disease.
- Lixisenatide - A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes.
- Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. Reply.
- Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis.
- Liraglutide treatment is associated with progression of coronary artery fibrous plaque: a prospective 1-year follow-up study in asymptomatic patients with type 2 diabetes.
- Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity.
- Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
- Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score.
- Liraglutide exhibits anti-inflammatory activity through the activation of the PKA/CREB pathway.
- A two-step method preparation of semaglutide through solid-phase synthesis and inclusion body expression.
- GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
- Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction.
- Biological activity of EXf, a peptide analogue of exendin-4.
- Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.
- Identification of key candidate genes and pathways revealing the protective effect of liraglutide on diabetic cardiac muscle by integrated bioinformatics analysis.
- Glucagon-Like Peptide-1 Receptor Agonists-How Safe Are They?
- Cardiovascular effects of tirzepatide.
- Inhibitory effects of peripheral administration of exendin-4 on food intake are attenuated by lesions of the central nucleus of amygdala.
- Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
- Effects of Liraglutide and Vitamin E in Fructose-Induced Metabolic Syndrome in Rats.
- Comparisons of efficacy and safety in insulin glargine and lixisenatide plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes.
- Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study.
- Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.
- Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care system.
- Sex-Differences in Response to Treatment with Liraglutide 3.0 mg.
- 'This Is My Decision': A Qualitative Study of Individuals' Perspectives on Use of Semaglutide for Weight Loss.
- Dulaglutide as a demethylating agent to improve the outcome of breast cancer.
- Sodium glycocholate liposome encapsulated semaglutide increases oral bioavailability by promoting intestinal absorption.
- Glucagon-like peptide-1 analog, liraglutide, regulates Sertoli cell energy metabolism.
- Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial.
- Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity.
- Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients?
- Efficacy and Tolerability of Semaglutide in Patients With Type-2 Diabetes Mellitus: Experience of a Tertiary Care Hospital, Pakistan.